These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Prospective observational study of Garske-Román U; Sandström M; Fröss Baron K; Lundin L; Hellman P; Welin S; Johansson S; Khan T; Lundqvist H; Eriksson B; Sundin A; Granberg D Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):970-988. PubMed ID: 29497803 [TBL] [Abstract][Full Text] [Related]
14. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of peptide receptor radionuclide therapy with Kobayashi N; Takano S; Ito K; Sugiura M; Ogawa M; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Kaneta T; Utsunomiya D; Hata M; Inoue T; Hosono M; Kinuya S; Ichikawa Y Ann Nucl Med; 2021 Dec; 35(12):1332-1341. PubMed ID: 34533700 [TBL] [Abstract][Full Text] [Related]
16. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205 [TBL] [Abstract][Full Text] [Related]
17. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Parghane RV; Talole S; Prabhash K; Basu S Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500 [TBL] [Abstract][Full Text] [Related]
18. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting. Kalshetty A; Ramaswamy A; Ostwal V; Basu S Nucl Med Commun; 2018 Dec; 39(12):1143-1149. PubMed ID: 30308585 [TBL] [Abstract][Full Text] [Related]
19. Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival. Löser A; Schwarzenböck SM; Heuschkel M; Willenberg HS; Krause BJ; Kurth J Nucl Med Commun; 2018 Mar; 39(3):236-246. PubMed ID: 29315138 [TBL] [Abstract][Full Text] [Related]
20. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function. Ranade R; Basu S J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]